RainDance Technologies CEO to Present at Transformational Tools Panel
Share:
LEXINGTON, MASSACHUSETTS, U.S.A., May 5, 2009 -- Christopher McNary, RainDance Technologies President and Chief Executive Officer, will discuss the impact of new transformational tools shaping life sciences research during a panel session at the 2009 BIO International Convention in Atlanta on May 20, 2009.
The session, Transformational Tools: How New Research Technologies Are Changing the Rules of the Game, will review how the accessibility and power of these new tools are empowering individual scientists to conduct research that was formerly infeasible, unaffordable, or threatening to the research status quo.
In his remarks, McNary will discuss how exciting new technologies are enabling researchers to rethink the way they design experiments and approach discovery, permitting the achievement of previously unattainable breakthrough science. He will cite that the capabilities of his company's RainStormTM microdroplet-based technology platform can be applied across a wide range of biomedical research applications. For example, McNary will describe how a researcher can collect a heterogeneous group of cells of interest, such as a cancer sample, break it down into homogeneous collections of primary cells such as tumor and stem cells, capture and interrogate these as single cells, and perform scientific analyses. This capability will help make exciting strides in understanding the fundamental biology of complex disease.
In addition, McNary will explain how the RainStorm platform also is being applied in collaboration with sanofi-aventis to develop game-changing high-throughput screening methodologies for drug discovery. This work will accelerate the discovery process by enabling pharmaceutical companies to make better and faster decisions about what compounds should be pulled through their development pipelines. McNary will review how these new workflows minimize experimental unknowns, permit simple sample manipulation, and generate accurate measurements at levels unimaginable only a few years ago.
McNary and the other chief executives on the panel also will describe the radical innovations, new perspectives, and diverse disciplines underlying these new technologies, as well as challenges to development and commercialization.
To learn more, visit the RainDance Technologies Website at www.raindancetech.com, or call 781-861-6300.
For more information about the 2009 BIO International Convention, visit http://convention.bio.org/.
About RainDance Technologies, Inc.
RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company's technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.
RainDance's initial application will focus on the targeted resequencing of the human genome - one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
For more information, please visit www.raindancetech.com.
